Business Wire

AZ-AXWAY

1.7.2024 18:43:32 CEST | Business Wire | Press release

Share
Axway Named a Leader in New API Management Software Report

Axway (Euronext: AXW.PA), a leading provider of API management and integration software, is proud to announce that it has been positioned as a Leader in The Forrester Wave™: API Management Software, Q3 2024, published on July 1, 2024.¹

"We are always honored when our customers share the positive experiences and outcomes they have had with Axway," said Vince Padua, Chief Product Officer at Axway. "We're invested in their success, providing the expertise and guidance needed to treat APIs as strategic business products.”

Axway was one of 15 select companies that Forrester invited to participate in its evaluation, The Forrester Wave™: API Management Software, Q3 2024. In this evaluation of its Amplify API Management, Axway earned the highest scores possible in seven evaluation criteria, including federated gateway management, API product management, and adoption.

“This recognition validates for us our unique API business strategy program, which is just one example of how we go above and beyond to ensure you extract maximum value from API investments. We empower organizations with universal API management tools that break down barriers and provide a single source of truth for the entire API landscape,” said Padua.

The report notes: “Axway focuses on digital business that is multicloud, multiprotocol, and multigateway. Its roadmap seeks to deliver a more unified product line, non-REST protocol enhancements, more gateway federation, AI for API creation and consumption, and gateway modernization... It is the only vendor in this evaluation to provide robust support for third-party federated gateways...” ¹

“The Amplify platform lets you discover, use, and govern APIs across multiple gateways, vendors, and environments, simplifying adoption and use of APIs. But providing an industry-leading API management solution isn’t enough,” adds Padua. “Just as essential is accompanying our customers in designing an API management strategy that will drive the best results from a company’s investment.”

According to the report, “Reference customers say Axway is a supportive partner that listens to its customers. They also love its support for third-party gateways.” ¹

With Amplify API Management, the global manufacturing and engineering innovator Bosch was able to accelerate product and service innovation.

“We manage over 2,000 APIs using Amplify API Management, with a volume of several hundred million transactions per month. These APIs enable a wide range of use cases, from connecting SAP S/4HANA with other line-of-business solutions to supporting smart heating systems for office buildings,” said David Geiger, Head of API Management at Bosch Digital.

“And with Amplify Marketplace, developers can easily find the right APIs without traversing the entire organization; this saves a huge amount of time.”

Baird, an investment bank and financial services company, drove rapid adoption with a central API catalog and secure self-service consumption with Axway.

“Today, our developers can see all the APIs their peers have developed, identify any application dependences, and check the source repository to see who last worked on it,” said Jim Cornelius, SVP, IT Architect at Baird. “With a central view of which APIs are available, our teams can leverage already-existing code or even an entire API created by another team to accelerate their own development work. Without a doubt, this capability is reducing duplication of effort in our development process — helping us to minimize our time to market for new data-driven services.”

Click here to view a complimentary copy of The Forrester Wave™ report.

¹ The Forrester Wave™: API Management Software, Q3 2024, Forrester Research, Inc., July 1, 2024

About Axway

Axway is an independent technology provider that sustainably grows enduring value for our customers based on a history of trust, security, and stability that goes back nearly 25 years. Our extensive portfolio, which encompasses Managed File Transfer, B2B Integration, Financial Accounting Hub, and comprehensive API management through Amplify, empowers organizations to seamlessly integrate their internal and external ecosystems and succeed in a shifting digital business landscape. Learn more at axway.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701226257/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye